Warner-lambert Company

Pfizer Corporation

Thomas Capiris

Jagadish C Sircar

David T Connor

David Christopher Horwell

David Juergen Wustrow

Justin Stephen Bryans

Clare Octavia Kneen

Lawrence D Wise

Paul C Unangst

Thomas R Belliotti

Steven Robert Miller

Novel gamma aminobutyric acids of formula (I) are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammation, and gastrointestinal damage. Processes for the preparation and intermediates useful in the preparation are also disclosed.

Amines as pharmaceutical agents

Novel amines of formulas (1), (1C), (1F), (1G) and (1H) or a pharmaceutical acceptable salt thereof wherein n is an integer of from 0 to 2; m is an integer of from 0 to 3; R is sulfonamide, amide, phosphonic acid, heterocycle, sulfonic acid, or hydroxamic acid; A&prime; is a bridged ring selected from (1), (2), (3), (4), (5) wherein is the point of attachment; Z to Z are each independently selected from hydrogen and methyl; o is an integer of from 1 to 4; and p is an integer of from 0 to 2. In formula (1) above R cannot be sulfonic acid when m is 2 and n is 1 are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, especially irritable bowel syndrome.

1-substituted-1-aminomethyl-cycloalkane derivatives (&equals;gabapentin analogues), their preparation and their use in the treatment of neurological disorders

This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.

Method of treating psychosis and schizophrenia

Thiophene-2-carboxamidotetrazoles inhibit the Mac-1 integrin and are thus useful for treating diseases mediated by Mac-1 adhesion, including inflammatory disorders.

Thiophene-2-carboxamidotetrazoles and pharmaceutical use thereof

The present invention is a novel compound which is a 3,5-di-t-butyl-4-hydroxyphenylmethylhydroxylamine or derivative thereof and a pharmaceutically acceptable acid addition or base salt thereof, pharmaceutical composition and methods of use therefor. The invention compounds are now found to have activity as inhibitors of one or both of cyclooxygenase and 5-lipoxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like.

3,5-di-t-butyl-4-hydroxyphenylmethylhydroxylamines and their

3,5-di-t-butyl-4-hydroxylphenylmethylhydroxylamines and their

The novel 3,5-di-tertiary-butyl-4-hydroxyphenyloxazolyl methanones and methanone oximes of the present invention are antiinflammatory agents having activity as inhibitors of 5-lipoxygenase, cyclooxygenase or both.

3,5-di-tertiary-butyl-4-hydroxphenyl oxazolyl methanones and related

The novel 3,5-di-tertiary-butyl 4-hydroxyphenylimidazolyl methanones and methanone oximes of the present invention are antiinflammatory agents having activity as inhibitors of 5-lipoxygenase, cyclooxygenase or both.

3,5-di-tertiary-butyl-4-hydroxyphenyl imidazolyl methanones and related

The novel 3,5-di-tertiary-butyl-4-hydroxyphenylthiazolyl, -oxazolyl, or -imidazolyl methanones and methanone oximes of the present invention are antiinflammatory agents having activity as inhibitors of 5-lipoxygenase, cyclooxygenase or both.

3,5-di-tertiary-butyl-4-hydroxyphenyl thiazolyl, oxazolyl, and

4-Hydroxy-N-[5-[(substituted hetero)methyl]-3-isoxazolyl]-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides as agents for treating pain in mammals resulting from inflammation.

5-substituted-3-aminoisoxazole compounds

3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides

Certain pyrazolo[5,1-b]quinazolin-9-(4H)-ones are disclosed. These compounds prevent the allergic response in mammals. Novel alkylthioanthranilic acids, useful as intermediates, are also disclosed.

Pyrazolo[5,1-b]quinazolin-9-(4H)-ones and anti-allergic pharmaceutical

Certain 4,9-dihydro-9-oxo-N-1H-tetrazol-5-yl-pyrazolo[5,1-b]quinazoline-2-carboxam ides are disclosed. These compounds prevent the allergic response in mammals.

Growing community of inventors

Plymouth, MI, United States of America

Thomas Capiris